UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
SCHEDULE
14A
(RULE
14a-101)
SCHEDULE
14A INFORMATION
Proxy
Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934 (Amendment No. ___ )
Filed by
the Registrant þ
Filed by
a Party other than the Registrant o
Check the
appropriate box:
|
o
|
Preliminary
proxy statement.
|
|
o
|
Confidential, for use of the
Commission Only (as permitted by
Rule 14a-6(e)(2)).
|
|
o
|
Definitive
Proxy Statement.
|
|
þ
|
Definitive
Additional Materials.
|
|
o
|
Soliciting
Material Pursuant to §240.14a-12.
|
|
Orthofix
International N.V.
|
|
(Name
of Registrant as Specified in its Charter)
|
|
(Name
of Person(s) Filing Proxy Statement, if Other Than the
Registrant)
|
Payment
of Filing Fee (Check the appropriate box):
|
þ
|
No
fee required.
|
|
o
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
|
|
(1)
|
|
Title
of each class of securities to which transaction applies:
|
|
(2)
|
|
Aggregate
number of securities to which transaction applies:
|
|
(3)
|
|
Per
unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee
is calculated and state how it was determined): ____________________________
|
|
(4)
|
|
Proposed
maximum aggregate value of transaction:
|
|
(5)
|
|
Total
fee paid:
|
|
o
|
Fee
paid previously with preliminary
materials.
|
o Check
box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement number,
or the form or schedule and the date of its filing.
|
(1)
|
|
Amount
Previously Paid:
|
|
(2)
|
|
Form,
Schedule or Registration Statement No.:
|
|
(3)
|
|
Filing
Party:
|
|
(4)
|
|
Date
Filed:
|
|
Contact:
|
Dan
Yarbrough, Vice President of Investor
Relations
|
danyarbrough@orthofix.com
(617)
912-2903
Orthofix
International Files Definitive Proxy Statement
Boston,
MA, – (BUSINESS WIRE)
– Jan 12, 2009 –
Orthofix International N.V. (NASDAQ: OFIX) (the Company) announced today
that it has filed a Definitive Proxy Statement with the SEC objecting to a
proposal by Ramius LLC to call a special shareholder meeting.
About
Orthofix
Orthofix
International, N.V., a global medical device company, offers a broad line of
minimally invasive surgical, and non-surgical, products for the spine,
orthopedic, and sports medicine market sectors that address the lifelong
bone-and-joint health needs of patients of all ages–helping them achieve a more
active and mobile lifestyle. Orthofix’s products are widely distributed around
the world to orthopedic surgeons and patients via Orthofix’s sales
representatives and its subsidiaries, including BREG, Inc. and Blackstone
Medical, Inc., and via partnerships with other leading orthopedic product
companies. In addition, Orthofix is collaborating in R&D partnerships with
leading medical institutions such as the Musculoskeletal Transplant Foundation,
the Orthopedic Research and Education Foundation, Rutgers University, the
Cleveland Clinic Foundation, Texas Scottish Rite Hospital for Children and
National Osteoporosis Institute. For more information about Orthofix, please
visit www.orthofix.com.